anastrozole has been researched along with Local Neoplasm Recurrence in 124 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer." | 9.22 | Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. ( Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G, 2016) |
| "Aromatase inhibitors are superior to tamoxifen as adjuvant therapy in postmenopausal patients with hormone-responsive breast cancer." | 9.19 | Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. ( Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I, 2014) |
| " Premenopausal women with estrogen receptor (ER)-positive and/or progesterone-receptor positive, advanced or recurrent breast cancer refractory to an LH-RH analogue plus TAM received goserelin (GOS) in conjunction with anastrozole (ANA)." | 9.17 | Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. ( Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y, 2013) |
| "Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer." | 9.16 | Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. ( Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C, 2012) |
| "To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D1 we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial." | 9.16 | Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. ( Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L, 2012) |
| "These data show long-term safety findings and establish clearly the long-term efficacy of anastrozole compared with tamoxifen as initial adjuvant treatment for postmenopausal women with hormone-sensitive, early breast cancer, and provide statistically significant evidence of a larger carryover effect after 5 years of adjuvant treatment with anastrozole compared with tamoxifen." | 9.13 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS, 2008) |
| "In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial." | 9.12 | Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. ( Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C, 2007) |
| "ATAC, a randomized, double-blind trial, compared tamoxifen (20 mg) with anastrozole ('Arimidex') (1 mg) alone, and the combination of anastrozole plus tamoxifen (combination), as adjuvant endocrine treatment for postmenopausal patients with early breast cancer." | 9.10 | 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. ( Buzdar, AU, 2003) |
| "The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC)." | 9.10 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana ( Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T, 2003) |
| "Current prevention trials have shown that tamoxifen can reduce the incidence of breast cancer by about 30%-40% in high-risk women, but that the risk of thromboembolic disease and endometrial cancer are increased about twofold." | 8.82 | Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). ( Cuzick, J, 2003) |
| "Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 8.81 | Anastrozole: in early breast cancer. ( Faulds, DM; Wellington, K, 2002) |
| "A 73- year-old woman was diagnosed by chance with late recurrence of HR+ breast cancer 21 years after undergoing radical resection followed by adjuvant anastrozole for 5 years for stage Ⅲb right breast cancer." | 8.02 | [A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole]. ( Araki, K; Hamada, M; Ikeda, T; Minamoto, K, 2021) |
| "Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate." | 7.85 | Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. ( Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N, 2017) |
| "Tumor specimens from a subset of postmenopausal patients with hormone receptor-positive early-stage (stages I, II, and IIIA) breast cancer, who were enrolled in the randomized double-blind Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial, were genotyped for variants in CYP2D6 (N = 1203 patients: anastrozole [trade name: Arimidex] group, n = 615 patients; tamoxifen group, n = 588 patients) and UDP-glucuronosyltransferase-2B7 (UGT2B7), whose gene product inactivates endoxifen (N = 1209 patients; anastrozole group, n = 606 patients; tamoxifen group, n = 603 patients)." | 7.78 | CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. ( Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN, 2012) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 7.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "The 5-year completed treatment analysis of the Anastrozole and Tamoxifen-Alone or in Combination (ATAC) trial showed the superiority of anastrozole over tamoxifen for reduction of disease progression in patients with hormone receptor-positive (HR+) early breast cancer (EBC)." | 7.73 | Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. ( Annemans, L; Moeremans, K, 2006) |
| "To conduct an economic analysis comparing tamoxifen and anastrozole (Arimidex) in the adjuvant treatment of hormone receptor-positive (HR+), post-menopausal early breast cancer patients." | 7.73 | Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. ( Rocchi, A; Verma, S, 2006) |
| "A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years." | 7.72 | Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. ( Hillner, BE, 2004) |
| "We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department." | 7.72 | [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004) |
| "To evaluate the response rate and survival duration of patients treated with anastrozole for metastatic breast cancer, who had previously received at least one line of hormonal therapy." | 7.71 | Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. ( Cohen, Y; Geffen, DB; Lavrenkov, K; Man, S, 2002) |
| "Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require much larger patient numbers and longer follow-up." | 6.71 | Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 6.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| " RS, alone or in combination with clinicopathological variables expressed by the Clinical Treatment Score (CTS), for the prognostication of DR in a retrospective cohort of 776 postmenopausal patients with ER+/HER2-breast cancer enrolled in the translational arm of the randomised Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial." | 5.51 | Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. ( Buus, R; Chu, K; Colleoni, M; Cuzick, J; Di Fiore, PP; Disalvatore, D; Dowsett, M; Freddi, S; Maisonneuve, P; Montani, F; Pece, S; Sestak, I; Tillhon, M; Veronesi, P; Viale, G, 2022) |
| "The Austrian Breast and Colorectal Cancer Study Group (ABCSG) 8 RCT compared 5 years of tamoxifen with tamoxifen for 2 years followed by anastrozole for 3 years in postmenopausal women with endocrine receptor-positive breast cancer." | 5.41 | PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. ( Balic, M; Bartsch, R; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Herz, W; Moinfar, F; Rudas, M; Schaper, C, 2021) |
| "In this prospective, phase 3 trial, we randomly assigned postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy to receive the aromatase inhibitor anastrozole for an additional 2 years (2-year group, receiving a total of 7 years) or an additional 5 years (5-year group, receiving a total of 10 years)." | 5.41 | Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. ( Balic, M; Bartsch, R; Bjelic-Radisic, V; Brunner, C; Deutschmann, C; Egle, D; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Greil-Ressler, S; Haslbauer, F; Heck, D; Jakesz, R; Kacerovsky-Strobl, S; Manfreda, D; Melbinger-Zeinitzer, E; Rinnerthaler, G; Sevelda, P; Singer, CF; Soelkner, L; Steger, GG; Suppan, C; Thaler, J; Trapl, H; Wette, V; Wieder, U; Wimmer, K, 2021) |
| "Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer." | 5.35 | [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. ( Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N, 2008) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 5.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "A subset of patients with estrogen- or progesterone-positive platinum-resistant or platinum-refractory recurrent epithelial ovarian cancers derives clinical benefit from anastrozole, with acceptable toxicity." | 5.24 | Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. ( Beale, PJ; Bonaventura, A; DeFazio, A; Friedlander, ML; Goh, JCH; Grant, PT; Hadley, AM; Mapagu, C; Martyn, J; McNally, OM; Mileshkin, LR; OʼConnell, RL; Scurry, J; Sjoquist, KM, 2017) |
| "Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer." | 5.22 | Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. ( Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G, 2016) |
| "Aromatase inhibitors are superior to tamoxifen as adjuvant therapy in postmenopausal patients with hormone-responsive breast cancer." | 5.19 | Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. ( Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I, 2014) |
| " Premenopausal women with estrogen receptor (ER)-positive and/or progesterone-receptor positive, advanced or recurrent breast cancer refractory to an LH-RH analogue plus TAM received goserelin (GOS) in conjunction with anastrozole (ANA)." | 5.17 | Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. ( Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y, 2013) |
| "Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer." | 5.16 | Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. ( Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C, 2012) |
| "To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D1 we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial." | 5.16 | Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. ( Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L, 2012) |
| "This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses." | 5.14 | 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. ( Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K, 2009) |
| "The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized clinical trial in which postmenopausal women with early-stage breast cancer were randomly assigned to receive oral daily anastrozole (1 mg) alone, tamoxifen (20 mg) alone, or the combination in a double-blind fashion." | 5.14 | Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. ( Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I, 2010) |
| "These data show long-term safety findings and establish clearly the long-term efficacy of anastrozole compared with tamoxifen as initial adjuvant treatment for postmenopausal women with hormone-sensitive, early breast cancer, and provide statistically significant evidence of a larger carryover effect after 5 years of adjuvant treatment with anastrozole compared with tamoxifen." | 5.13 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS, 2008) |
| "To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-receptor (PgR) expression and human epidermal growth factor 2 (HER-2) status with time to recurrence (TTR) in postmenopausal women with hormone receptor-positive primary breast cancer treated with anastrozole or tamoxifen as adjuvant therapy." | 5.13 | Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. ( Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N, 2008) |
| "The Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial was the first trial to explore the use of aromatase inhibitors in post-menopausal women with early breast cancer and is the largest published cancer treatment trial in breast cancer." | 5.12 | The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. ( Cuzick, J, 2007) |
| "In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial." | 5.12 | Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. ( Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C, 2007) |
| "Arimidex, tamoxifen alone, or in combination (ATAC) trial of anastrozole (Arimidex) versus tamoxifen or a combination of the two in 9,366 postmenopausal patients with primary breast cancer found a significant improvement in disease-free survival and time to recurrence (TTR) for anastrozole compared with tamoxifen, that was restricted to patients with hormone receptor-positive (ie, estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+]) disease, the target population for these therapies." | 5.11 | Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. ( Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C, 2005) |
| " In this study, adjuvant tamoxifen and anastrozole ('Arimidex') were compared alone and in combination in more than 9000 women with breast cancer." | 5.11 | Biomarker investigations from the ATAC trial: the role of TA01. ( Dowsett, M, 2004) |
| "The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC)." | 5.10 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana ( Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T, 2003) |
| "ATAC, a randomized, double-blind trial, compared tamoxifen (20 mg) with anastrozole ('Arimidex') (1 mg) alone, and the combination of anastrozole plus tamoxifen (combination), as adjuvant endocrine treatment for postmenopausal patients with early breast cancer." | 5.10 | 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. ( Buzdar, AU, 2003) |
| "For young patients with hormone receptor-positive early breast cancer, tamoxifen for at least 5 years is the standard endocrine treatment." | 5.01 | [Endocrine adjuvant treatment specific features for young breast cancer women]. ( Petit, T, 2019) |
| "Aromatase inhibitors (AIs) have largely replaced tamoxifen as adjuvant hormonal therapy for postmenopausal women with early breast cancer." | 4.86 | Adjuvant endocrine therapy for early breast cancer: the story so far. ( Gradishar, WJ, 2010) |
| "To establish the clinical and cost-effectiveness of aromatase inhibitors (AIs) anastrozole, letrozole and exemestane compared with tamoxifen in the adjuvant treatment of early oestrogen receptor-positive breast cancer in postmenopausal women." | 4.84 | Hormonal therapies for early breast cancer: systematic review and economic evaluation. ( Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L, 2007) |
| "Adjuvant hormonal therapy for patients with endocrine sensitive breast cancer has been dominated for several decades by the gold standard tamoxifen." | 4.83 | The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. ( Gligorov, J; Nabholtz, JM, 2006) |
| "Tamoxifen has been the standard of care for adjuvant endocrine therapy of early breast cancer." | 4.82 | Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? ( Baum, M, 2005) |
| "Recent advances have been made in the hormonal treatment of breast cancer with the advent of third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane)." | 4.82 | Aromatase inhibitors in breast cancer therapy. ( Buzdar, AU, 2003) |
| "Current prevention trials have shown that tamoxifen can reduce the incidence of breast cancer by about 30%-40% in high-risk women, but that the risk of thromboembolic disease and endometrial cancer are increased about twofold." | 4.82 | Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). ( Cuzick, J, 2003) |
| "Recent trials have indicated that the aromatase inhibitors (anastrozole, letrozole, exemestane) are more effective than tamoxifen, the standard adjuvant treatment for estrogen receptor-positive breast cancer, both in adjuvant and first-line advanced settings." | 4.82 | Anastrozole. ( Cuzick, J, 2005) |
| "Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 4.81 | Anastrozole: in early breast cancer. ( Faulds, DM; Wellington, K, 2002) |
| "A 73- year-old woman was diagnosed by chance with late recurrence of HR+ breast cancer 21 years after undergoing radical resection followed by adjuvant anastrozole for 5 years for stage Ⅲb right breast cancer." | 4.02 | [A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole]. ( Araki, K; Hamada, M; Ikeda, T; Minamoto, K, 2021) |
| "Quantitative immune scores of cell abundance and spatial heterogeneity were computed using a fully automated hematoxylin and eosin-stained image analysis algorithm and spatial statistics for 1178 postmenopausal patients with ER+ breast cancer treated with five years' tamoxifen or anastrozole." | 3.88 | Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. ( Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y, 2018) |
| "Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate." | 3.85 | Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. ( Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N, 2017) |
| "One thousand four hundred seventy-eight postmenopausal women with estrogen receptor (ER)+ early breast cancer (EBC) treated with tamoxifen or tamoxifen followed by anastrozole from the prospective randomized ABCSG-8 trial were entered into this study." | 3.80 | Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. ( Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J, 2014) |
| " Analysis of BAG1 was performed on archival tumour blocks from patients from the anastrozole and tamoxifen arms of the ATAC trial of 5 years endocrine therapy in postmenopausal women with oestrogen receptor (ER)-positive primary breast cancer." | 3.79 | Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. ( Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I, 2013) |
| "mRNA from 1,017 patients with ER-positive primary breast cancer treated with anastrozole or tamoxifen in the ATAC trial was assessed for ROR using the NanoString nCounter." | 3.79 | Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. ( Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J, 2013) |
| " Here, we report an advanced case of breast cancer with vertebra-Th7 metastasis that showed complete response to combined treatments with formalin-fixed autologous tumor vaccine (AFTV), palliative radiation therapy with 36 Gy, and adjuvant chemotherapy with standardized CEF (cyclophosphamide, epirubicin, and 5FU), zoledronic acid, and aromatase inhibitors following mastectomy for the breast tumor." | 3.79 | Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report. ( Kuranishi, F; Ohno, T, 2013) |
| "Tumor specimens from a subset of postmenopausal patients with hormone receptor-positive early-stage (stages I, II, and IIIA) breast cancer, who were enrolled in the randomized double-blind Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial, were genotyped for variants in CYP2D6 (N = 1203 patients: anastrozole [trade name: Arimidex] group, n = 615 patients; tamoxifen group, n = 588 patients) and UDP-glucuronosyltransferase-2B7 (UGT2B7), whose gene product inactivates endoxifen (N = 1209 patients; anastrozole group, n = 606 patients; tamoxifen group, n = 603 patients)." | 3.78 | CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. ( Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN, 2012) |
| "A gene expression signature derived from ER(+) breast cancer cells with acquired hormone independence predicted tumor response to aromatase inhibitors and associated with clinical markers of resistance to tamoxifen." | 3.77 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. ( Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H, 2011) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 3.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the first follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation between these symptoms and subsequent recurrence." | 3.74 | Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. ( Cella, D; Cuzick, J; Fallowfield, L; Sestak, I, 2008) |
| "The 5-year completed treatment analysis of the Anastrozole and Tamoxifen-Alone or in Combination (ATAC) trial showed the superiority of anastrozole over tamoxifen for reduction of disease progression in patients with hormone receptor-positive (HR+) early breast cancer (EBC)." | 3.73 | Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. ( Annemans, L; Moeremans, K, 2006) |
| "To conduct an economic analysis comparing tamoxifen and anastrozole (Arimidex) in the adjuvant treatment of hormone receptor-positive (HR+), post-menopausal early breast cancer patients." | 3.73 | Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. ( Rocchi, A; Verma, S, 2006) |
| "A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years." | 3.72 | Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. ( Hillner, BE, 2004) |
| "We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department." | 3.72 | [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004) |
| "To evaluate the response rate and survival duration of patients treated with anastrozole for metastatic breast cancer, who had previously received at least one line of hormonal therapy." | 3.71 | Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. ( Cohen, Y; Geffen, DB; Lavrenkov, K; Man, S, 2002) |
| "Anastrozole was well tolerated." | 2.90 | PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; DeFazio, A; Friedlander, M; Goh, J; Grant, P; Kok, PS; Mapagu, C; O'Connell, RL; Scurry, J; Sjoquist, K, 2019) |
| "Anastrozole was well-tolerated." | 2.90 | PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; Davis, A; deFazio, A; Friedlander, M; Goh, J; Grant, P; Kennedy, CJ; McNally, O; Mileshkin, L; Moujaber, T; O'Connell, RL; Scurry, J; Sjoquist, KM; Sykes, P; Tan, K; Tang, M, 2019) |
| "Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require much larger patient numbers and longer follow-up." | 2.71 | Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 2.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "The management of ductal carcinoma in situ (DCIS) with endocrine therapy remains controversial." | 2.66 | Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis. ( Drokow, EK; Li, Z; Liu, J; Ma, X; Ren, J; Shao, S; Shi, X; Tan, L; Xue, C; Yan, Y; Zhang, L; Zhang, X; Zhang, Y, 2020) |
| "Type I endometrial cancer is a common tumor of the female genital tract." | 2.53 | Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. ( Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F, 2016) |
| "However, concern for under- or over-treatment of DCIS has led many surgeons to question historically standardized approaches and instead begin to tailor treatment based on individual prognostic indicators." | 2.52 | Ductal Carcinoma In Situ: Treatment Update and Current Trends. ( Kuerer, H; Mitchell, KB, 2015) |
| "Here we report a case of breast cancer that recurred after a 39-year latency period." | 2.50 | [A case of local recurrence developing thirty-nine years after mastectomy for breast cancer]. ( Kawano, K; Tashima, Y, 2014) |
| "Medico-economic evaluation of breast cancer is very significant and valuable and is expected to stimulate efficient utilization of healthcare resources." | 2.44 | Economic evaluation of the prevention and treatment of breast cancer--present status and open issues. ( Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K, 2007) |
| "Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy." | 2.44 | Reducing the risk of late recurrence in hormone-responsive breast cancer. ( Cufer, T, 2007) |
| "Hormone receptor-positive breast cancer is increasingly considered a chronic disease, as there remains an ongoing risk of local and distant relapse for years after diagnosis." | 2.44 | The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. ( Pennery, E, 2008) |
| " Clinical trials have begun to define the role of these agents and their unique side-effect profiles." | 2.42 | Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. ( Harwood, KV, 2004) |
| "From the group with therapy change, 'disease progression' was reason of change in 124 (58." | 1.62 | Switching of Hormone Therapies in Breast Cancer Women. ( Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R, 2021) |
| "We report a case of local recurrence of breast cancer 8 years after mastectomy." | 1.56 | [Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report]. ( Adachi, K; Hirano, T; Sakurai, K; Suzuki, S, 2020) |
| "Metastatic breast cancer (MBC) represents a wide spectrum of heterogeneous conditions with different secondary spread sites, time to relapse and biology." | 1.51 | Long-Term Survival and Complete Response to ( Sedloev, T; Spirdonov, J; Spiridonova, T; Usheva, S; Vasileva-Slaveva, M; Vlahova, A, 2019) |
| "Letrozole was administered post operatively in 55." | 1.46 | Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? ( Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G, 2017) |
| "Low-grade endometrial stromal sarcoma is very rare and difficult to diagnose in the early stage." | 1.42 | Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report. ( Horio, M; Ichihara, S; Inoue, T; Ishihara, Y; Ito, M; Kondo, I; Maeda, O; Matsumura, Y; Moritani, S; Sugiyama, K; Yamamoto, S, 2015) |
| "As most node-positive patients with HR+ breast cancer currently receive adjuvant chemotherapy improved methods for characterization of individuals' metastasis risk are needed to reduce overtreatment." | 1.42 | Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence ( Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H, 2015) |
| "ER+/HER2- breast cancers have a proclivity for late recurrence." | 1.39 | The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. ( Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE, 2013) |
| "To test this, we examined if accidental trauma or surgery, unrelated to the original cancer, might stimulate the growth of dormant micrometastases and be related to an increase in the recurrence rate in the period after the event." | 1.38 | Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates? ( Allawi, Z; Baum, M; Cuzick, J, 2012) |
| "Anastrozole was effective to recurrent low-grade ESS even after being refractory to progestin therapy." | 1.37 | Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. ( Ikeda, Y; Kawana, K; Kozuma, S; Nakagawa, S; Oda, K; Shoji, K; Takazawa, Y; Taketani, Y; Yasugi, T, 2011) |
| "Two hundred and ninety-two breast cancer patients who had undergone breast-conserving surgery and been treated with Tam or Ana, with or without RT, were retrospectively analyzed." | 1.37 | Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy. ( Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S, 2011) |
| "Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes." | 1.37 | Predictive algorithms for adjuvant therapy: TransATAC. ( Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L, 2011) |
| "Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer." | 1.35 | [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. ( Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N, 2008) |
| "When tamoxifen therapy was discontinued after 4 years of use in the first patient, her DM rash worsened and remained difficult to control with conventional immunosuppressant medication." | 1.33 | Improvement in dermatomyositis rash associated with the use of antiestrogen medication. ( Sereda, D; Werth, VP, 2006) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 1.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Modern treatment of cancer of the breast is based on established prognostic factors (patient age, receptor status, tumor size, lymph node involvement, tumor grading), and thus takes the patient's individual risk profile into account." | 1.32 | [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]. ( Höffken, K; Sayer, HG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 56 (45.16) | 29.6817 |
| 2010's | 54 (43.55) | 24.3611 |
| 2020's | 14 (11.29) | 2.80 |
| Authors | Studies |
|---|---|
| Minamoto, K | 1 |
| Ikeda, T | 1 |
| Araki, K | 1 |
| Hamada, M | 1 |
| Oshima, K | 1 |
| Kikumori, K | 1 |
| Yanagawa, T | 1 |
| Egawa, C | 2 |
| Takatsuka, Y | 2 |
| Shinke, G | 1 |
| Katsuyama, S | 1 |
| Kawai, K | 1 |
| Hiraki, M | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Masuzawa, T | 1 |
| Hata, T | 1 |
| Takeda, Y | 1 |
| Murata, K | 1 |
| Pece, S | 1 |
| Sestak, I | 17 |
| Montani, F | 1 |
| Tillhon, M | 1 |
| Maisonneuve, P | 1 |
| Freddi, S | 1 |
| Chu, K | 1 |
| Colleoni, M | 2 |
| Veronesi, P | 1 |
| Disalvatore, D | 1 |
| Viale, G | 2 |
| Buus, R | 5 |
| Cuzick, J | 28 |
| Dowsett, M | 25 |
| Di Fiore, PP | 1 |
| Iwase, T | 1 |
| Saji, S | 1 |
| Iijima, K | 1 |
| Higaki, K | 2 |
| Ohtani, S | 1 |
| Sato, Y | 1 |
| Hozumi, Y | 2 |
| Hasegawa, Y | 1 |
| Yanagita, Y | 1 |
| Takei, H | 1 |
| Tanaka, M | 2 |
| Masuoka, H | 1 |
| Tanabe, M | 1 |
| Komoike, Y | 2 |
| Nakamura, T | 1 |
| Ohtsu, H | 1 |
| Mukai, H | 2 |
| Barron, S | 2 |
| Loughman, T | 2 |
| Fender, B | 1 |
| Ruiz, CL | 1 |
| Dynoodt, P | 1 |
| Wang, CA | 1 |
| O'Leary, D | 2 |
| Gallagher, WM | 2 |
| Petit, T | 1 |
| Ingle, JN | 1 |
| Kalari, KR | 1 |
| Barman, P | 1 |
| Shepherd, LE | 1 |
| Ellis, MJ | 2 |
| Goss, PE | 2 |
| Buzdar, AU | 4 |
| Robson, ME | 1 |
| Cairns, J | 1 |
| Carlson, EE | 1 |
| Eyman Casey, A | 1 |
| Hoskin, TL | 1 |
| Goodnature, BA | 1 |
| Haddad, TC | 1 |
| Goetz, MP | 1 |
| Weinshilboum, RM | 1 |
| Wang, L | 1 |
| Kronenwett, R | 3 |
| Ferree, S | 7 |
| Schnabel, CA | 3 |
| Baehner, FL | 3 |
| Mallon, EA | 2 |
| Medeiros, LM | 1 |
| Stahlschmidt, R | 1 |
| Ferracini, AC | 1 |
| Souza, CM | 1 |
| Juliato, CRT | 1 |
| Mazzola, PG | 1 |
| Adachi, K | 1 |
| Suzuki, S | 1 |
| Hirano, T | 1 |
| Sakurai, K | 1 |
| Fitzal, F | 6 |
| Filipits, M | 6 |
| Fesl, C | 5 |
| Rudas, M | 6 |
| Greil, R | 7 |
| Balic, M | 5 |
| Moinfar, F | 1 |
| Herz, W | 1 |
| Dubsky, P | 8 |
| Bartsch, R | 4 |
| Schaper, C | 5 |
| Gnant, M | 10 |
| Rinnerthaler, G | 1 |
| Steger, GG | 2 |
| Greil-Ressler, S | 1 |
| Heck, D | 1 |
| Jakesz, R | 8 |
| Thaler, J | 1 |
| Egle, D | 2 |
| Manfreda, D | 1 |
| Bjelic-Radisic, V | 1 |
| Wieder, U | 1 |
| Singer, CF | 4 |
| Melbinger-Zeinitzer, E | 1 |
| Haslbauer, F | 1 |
| Sevelda, P | 2 |
| Trapl, H | 1 |
| Wette, V | 1 |
| Wimmer, K | 1 |
| Gampenrieder, SP | 1 |
| Kacerovsky-Strobl, S | 1 |
| Suppan, C | 1 |
| Brunner, C | 1 |
| Deutschmann, C | 1 |
| Soelkner, L | 1 |
| Kainz, V | 1 |
| Bago-Horvath, Z | 2 |
| Regitnig, P | 1 |
| Halper, S | 1 |
| Hulla, W | 1 |
| Hlauschek, D | 1 |
| Banerjee, SN | 1 |
| Tang, M | 2 |
| O'Connell, RL | 3 |
| Sjoquist, K | 2 |
| Clamp, AR | 1 |
| Millan, D | 1 |
| Nottley, S | 1 |
| Lord, R | 1 |
| Mullassery, VM | 1 |
| Hall, M | 1 |
| Gourley, C | 2 |
| Bonaventura, T | 3 |
| Goh, JC | 1 |
| Sykes, P | 2 |
| Grant, PT | 2 |
| McNally, O | 2 |
| Alexander, L | 1 |
| Kelly, C | 1 |
| Carty, K | 1 |
| Divers, L | 1 |
| Bradshaw, N | 1 |
| Edmondson, RJ | 1 |
| Friedlander, M | 3 |
| Bonaventura, A | 1 |
| OʼConnell, RL | 1 |
| Mapagu, C | 2 |
| Beale, PJ | 1 |
| McNally, OM | 1 |
| Mileshkin, LR | 1 |
| Hadley, AM | 1 |
| Goh, JCH | 1 |
| Sjoquist, KM | 2 |
| Martyn, J | 1 |
| DeFazio, A | 3 |
| Scurry, J | 3 |
| Friedlander, ML | 1 |
| Fader, AN | 1 |
| Bergstrom, J | 1 |
| Jernigan, A | 1 |
| Tanner, EJ | 1 |
| Roche, KL | 1 |
| Stone, RL | 1 |
| Levinson, KL | 1 |
| Ricci, S | 1 |
| Wethingon, S | 1 |
| Wang, TL | 1 |
| Shih, IM | 1 |
| Yang, B | 1 |
| Zhang, G | 1 |
| Armstrong, DK | 1 |
| Gaillard, S | 1 |
| Michener, C | 1 |
| DeBernardo, R | 1 |
| Rose, PG | 2 |
| Heindl, A | 1 |
| Naidoo, K | 1 |
| Yuan, Y | 1 |
| Tsujio, G | 1 |
| Kashiwagi, S | 1 |
| Hatano, T | 1 |
| Asano, Y | 1 |
| Goto, W | 1 |
| Takada, K | 1 |
| Noda, S | 1 |
| Takashima, T | 1 |
| Onoda, N | 1 |
| Motomura, H | 1 |
| Hirakawa, K | 1 |
| Ohira, M | 1 |
| Denkert, C | 1 |
| Sgroi, D | 2 |
| Schnabel, C | 1 |
| Mallon, E | 3 |
| Regan, MM | 1 |
| Dodson, A | 1 |
| Thürlimann, B | 1 |
| Yeo, B | 1 |
| Brentnall, AR | 1 |
| Klintman, M | 1 |
| Cheang, MCU | 1 |
| Khabra, K | 1 |
| Gao, Q | 1 |
| Yan, Y | 1 |
| Zhang, L | 1 |
| Tan, L | 1 |
| Ma, X | 1 |
| Zhang, Y | 3 |
| Shao, S | 1 |
| Liu, J | 1 |
| Xue, C | 1 |
| Li, Z | 1 |
| Zhang, X | 1 |
| Drokow, EK | 1 |
| Shi, X | 1 |
| Ren, J | 1 |
| Ward, MC | 1 |
| Vicini, F | 1 |
| Chadha, M | 1 |
| Pierce, L | 1 |
| Recht, A | 1 |
| Hayman, J | 1 |
| Thaker, NG | 1 |
| Khan, A | 1 |
| Keisch, M | 1 |
| Shah, C | 1 |
| Amant, F | 2 |
| Beale, P | 2 |
| Grant, P | 2 |
| Davis, A | 1 |
| Mileshkin, L | 1 |
| Moujaber, T | 1 |
| Kennedy, CJ | 1 |
| Tan, K | 1 |
| Antill, Y | 2 |
| Goh, J | 2 |
| Kok, PS | 1 |
| Sedloev, T | 1 |
| Vlahova, A | 1 |
| Usheva, S | 1 |
| Vasileva-Slaveva, M | 1 |
| Spiridonova, T | 1 |
| Spirdonov, J | 1 |
| Boccardo, F | 1 |
| Guglielmini, P | 1 |
| Bordonaro, R | 1 |
| Fini, A | 1 |
| Massidda, B | 1 |
| Porpiglia, M | 1 |
| Roagna, R | 1 |
| Serra, P | 1 |
| Orzalesi, L | 1 |
| Ucci, G | 1 |
| Rubagotti, A | 1 |
| Nishimura, R | 1 |
| Anan, K | 1 |
| Yamamoto, Y | 2 |
| Shibuta, K | 1 |
| Sagara, Y | 1 |
| Ohno, S | 2 |
| Tsuyuki, S | 1 |
| Mase, T | 1 |
| Teramukai, S | 1 |
| Inari, H | 1 |
| Hashimoto, M | 1 |
| Uesugi, K | 1 |
| Goto, N | 1 |
| Hatori, S | 1 |
| Tanabe, H | 1 |
| Iwasaki, H | 1 |
| Vilquin, P | 1 |
| Villedieu, M | 1 |
| Grisard, E | 1 |
| Ben Larbi, S | 1 |
| Ghayad, SE | 1 |
| Heudel, PE | 1 |
| Bachelot, T | 1 |
| Corbo, L | 1 |
| Treilleux, I | 1 |
| Vendrell, JA | 1 |
| Cohen, PA | 1 |
| Kuranishi, F | 1 |
| Ohno, T | 1 |
| Lopez-Knowles, E | 4 |
| Sidhu, K | 2 |
| Dunbier, AK | 1 |
| Cowens, JW | 4 |
| Storhoff, J | 2 |
| Afentakis, M | 2 |
| Salter, J | 8 |
| Howell, T | 2 |
| Buzdar, A | 5 |
| Forbes, J | 5 |
| Sgroi, DC | 1 |
| Schroeder, B | 1 |
| Erlander, MG | 1 |
| Dunbier, A | 3 |
| Brase, JC | 1 |
| Dietze, O | 1 |
| Luisser, I | 1 |
| Klug, E | 1 |
| Sedivy, R | 1 |
| Bachner, M | 1 |
| Mayr, D | 1 |
| Schmidt, M | 1 |
| Gehrmann, MC | 1 |
| Petry, C | 1 |
| Weber, KE | 1 |
| Fisch, K | 1 |
| Stoeger, H | 2 |
| Mlineritsch, B | 2 |
| Kwasny, W | 3 |
| Knauer, M | 1 |
| Singer, C | 1 |
| Steger, G | 2 |
| Ressler, S | 1 |
| Liu, S | 1 |
| Nielsen, TO | 1 |
| Arnedos, M | 1 |
| Drury, S | 2 |
| A'Hern, R | 1 |
| Hills, M | 2 |
| Smith, IE | 2 |
| Reis-Filho, JS | 1 |
| Tashima, Y | 1 |
| Kawano, K | 1 |
| Esfahani, K | 1 |
| Ferrario, C | 1 |
| Le, P | 1 |
| Panasci, L | 1 |
| Shockman, S | 1 |
| Krug, L | 1 |
| Lountzis, N | 1 |
| Aihara, T | 1 |
| Yokota, I | 1 |
| Aogi, K | 1 |
| Iwata, H | 1 |
| Tamura, M | 1 |
| Fukuuchi, A | 1 |
| Makino, H | 1 |
| Kim, R | 1 |
| Andoh, M | 1 |
| Tsugawa, K | 1 |
| Yamaguchi, T | 1 |
| Ohashi, Y | 1 |
| Watanabe, T | 1 |
| Nielsen, T | 1 |
| Mitchell, KB | 1 |
| Kuerer, H | 1 |
| Maeda, O | 1 |
| Moritani, S | 1 |
| Ichihara, S | 1 |
| Inoue, T | 1 |
| Ishihara, Y | 1 |
| Yamamoto, S | 1 |
| Ito, M | 2 |
| Matsumura, Y | 1 |
| Sugiyama, K | 1 |
| Horio, M | 1 |
| Kondo, I | 1 |
| Bogliolo, S | 1 |
| Gardella, B | 1 |
| Dominoni, M | 1 |
| Musacchi, V | 1 |
| Cassani, C | 1 |
| Zanellini, F | 1 |
| De Silvestri, A | 1 |
| Gaggero, CR | 1 |
| Babilonti, L | 1 |
| Spinillo, A | 1 |
| Forbes, JF | 3 |
| Howell, A | 7 |
| Bonanni, B | 1 |
| Bundred, N | 1 |
| Levy, C | 1 |
| von Minckwitz, G | 1 |
| Eiermann, W | 1 |
| Neven, P | 1 |
| Stierer, M | 3 |
| Holcombe, C | 1 |
| Coleman, RE | 1 |
| Jones, L | 1 |
| Ellis, I | 2 |
| Schroeder, BE | 1 |
| Gervasini, G | 1 |
| Jara, C | 1 |
| Olier, C | 1 |
| Romero, N | 1 |
| Martínez, R | 1 |
| Carrillo, JA | 1 |
| Suman, VJ | 1 |
| Hoog, J | 1 |
| Goncalves, R | 1 |
| Sanati, S | 1 |
| Creighton, CJ | 1 |
| DeSchryver, K | 1 |
| Crouch, E | 1 |
| Brink, A | 1 |
| Watson, M | 1 |
| Luo, J | 1 |
| Tao, Y | 1 |
| Barnes, M | 1 |
| Budd, GT | 1 |
| Winer, E | 1 |
| Silverman, P | 1 |
| Esserman, L | 1 |
| Carey, L | 1 |
| Ma, CX | 1 |
| Unzeitig, G | 1 |
| Pluard, T | 1 |
| Whitworth, P | 1 |
| Babiera, G | 1 |
| Guenther, JM | 1 |
| Dayao, Z | 1 |
| Ota, D | 1 |
| Leitch, M | 1 |
| Olson, JA | 1 |
| Allred, DC | 1 |
| Hunt, K | 1 |
| Jinih, M | 1 |
| Relihan, N | 1 |
| Corrigan, MA | 1 |
| O'Reilly, S | 1 |
| Redmond, HP | 1 |
| Bellone, S | 1 |
| Shah, HR | 1 |
| McKenney, JK | 1 |
| Stone, PJ | 1 |
| Santin, AD | 1 |
| Nagykálnai, T | 1 |
| Maruyama, S | 1 |
| Hirano, Y | 1 |
| Shimo, T | 1 |
| Hashida, S | 1 |
| Iga, K | 1 |
| Inukai, M | 1 |
| Kanaya, Y | 1 |
| Yokoyama, N | 1 |
| Cella, D | 1 |
| Fallowfield, L | 1 |
| Thomas, RJ | 1 |
| Williams, M | 1 |
| Glen, J | 1 |
| Callam, M | 1 |
| Akashi-Tanaka, S | 2 |
| Shimizu, C | 2 |
| Ando, M | 2 |
| Shibata, T | 1 |
| Katsumata, N | 1 |
| Kouno, T | 1 |
| Terada, K | 2 |
| Shien, T | 2 |
| Yoshida, M | 1 |
| Hojo, T | 1 |
| Kinoshita, T | 2 |
| Fujiwara, Y | 2 |
| Yoshimura, K | 1 |
| Korach, J | 1 |
| Perri, T | 1 |
| Beiner, M | 1 |
| Davidzon, T | 1 |
| Fridman, E | 1 |
| Ben-Baruch, G | 1 |
| Blaha, P | 1 |
| Bachleitner-Hofmann, T | 1 |
| O'Connor, SM | 1 |
| Beriwal, S | 1 |
| Dabbs, DJ | 1 |
| Bhargava, R | 1 |
| Wale, C | 3 |
| Quinn, E | 2 |
| Baum, M | 6 |
| Bugarini, R | 1 |
| Shak, S | 1 |
| Gradishar, WJ | 1 |
| Shoji, K | 1 |
| Oda, K | 1 |
| Nakagawa, S | 1 |
| Kawana, K | 1 |
| Yasugi, T | 1 |
| Ikeda, Y | 1 |
| Takazawa, Y | 1 |
| Kozuma, S | 1 |
| Taketani, Y | 1 |
| Distler, W | 1 |
| Valakh, V | 1 |
| Trombetta, MG | 1 |
| Werts, ED | 1 |
| Labban, G | 1 |
| Khalid, MK | 1 |
| Kaminsky, A | 1 |
| Parda, D | 1 |
| Ishitobi, M | 1 |
| Nakahara, S | 1 |
| Motomura, K | 1 |
| Koyama, H | 1 |
| Inaji, H | 1 |
| Miller, TW | 1 |
| Balko, JM | 1 |
| Ghazoui, Z | 1 |
| Anderson, H | 1 |
| González-Angulo, AM | 1 |
| Mills, GB | 1 |
| Miller, WR | 1 |
| Wu, H | 1 |
| Shyr, Y | 1 |
| Arteaga, CL | 1 |
| Doughty, JC | 1 |
| Zabaglo, L | 2 |
| Pineda, S | 2 |
| Allawi, Z | 1 |
| Frederix, GW | 1 |
| Severens, JL | 1 |
| Hövels, AM | 1 |
| Raaijmakers, JA | 1 |
| Schellens, JH | 1 |
| Dubsky, PC | 1 |
| Pöstlberger, S | 2 |
| Samonigg, H | 1 |
| Tausch, C | 2 |
| Stöger, H | 1 |
| Haider, K | 2 |
| Luschin-Ebengreuth, G | 2 |
| Taucher, S | 2 |
| Filipcic, L | 1 |
| Rae, JM | 1 |
| Hayes, DF | 1 |
| Stearns, V | 1 |
| Thibert, JN | 1 |
| Haynes, BP | 1 |
| Lundgren, K | 1 |
| Brown, M | 1 |
| Landberg, G | 1 |
| Abdul Munem, A | 1 |
| Al-Bahrani, B | 1 |
| Mehdi, I | 1 |
| Kamona, A | 1 |
| Nadas, AM | 1 |
| Wellington, K | 1 |
| Faulds, DM | 1 |
| Mori, K | 1 |
| Chiba, N | 1 |
| Yonekawa, H | 1 |
| Sayer, HG | 1 |
| Höffken, K | 1 |
| Kmietowicz, Z | 1 |
| Houghton, J | 3 |
| Sahmoud, T | 1 |
| Baumann, ChK | 1 |
| Aebi, S | 1 |
| Leiser, AL | 1 |
| Hamid, AM | 1 |
| Blanchard, R | 1 |
| Hillner, BE | 1 |
| Okubo, S | 1 |
| Sonoo, H | 1 |
| Hirono, M | 1 |
| Nomura, T | 1 |
| Udagawa, K | 1 |
| Ikeda, M | 1 |
| Nakashima, K | 1 |
| Tanaka, K | 1 |
| Kurebayashi, J | 1 |
| Miyoshi, K | 1 |
| Ohtsuka, S | 1 |
| Inagaki, M | 1 |
| Ohsaki, T | 1 |
| Fuchimoto, S | 1 |
| Yumura, M | 1 |
| Nakagawa, T | 1 |
| Harwood, KV | 1 |
| Travis, K | 1 |
| Ebbs, SR | 1 |
| Dixon, JM | 1 |
| Skene, A | 1 |
| Griffith, C | 1 |
| Boeddinghaus, I | 1 |
| Detre, S | 1 |
| Ashley, S | 1 |
| Francis, S | 1 |
| Walsh, G | 1 |
| Sereda, D | 1 |
| Werth, VP | 1 |
| Tuma, RS | 1 |
| Rocchi, A | 1 |
| Verma, S | 1 |
| Freeman, SA | 1 |
| Modesitt, SC | 1 |
| Skedgel, C | 1 |
| Rayson, D | 1 |
| Dewar, R | 1 |
| Younis, T | 1 |
| Piskur, P | 1 |
| Sonc, M | 1 |
| Cufer, T | 2 |
| Borstnar, S | 1 |
| Mrhar, A | 1 |
| Moeremans, K | 1 |
| Annemans, L | 1 |
| Imai, H | 1 |
| Kuroi, K | 1 |
| Ohsumi, S | 1 |
| Ono, M | 1 |
| Shimozuma, K | 1 |
| Pötter, R | 1 |
| Handl-Zeller, L | 1 |
| Pakisch, B | 1 |
| Hammer, J | 1 |
| Schmid, M | 1 |
| Sedlmayer, F | 1 |
| Reiner, G | 1 |
| Kapp, K | 1 |
| Hofbauer, F | 1 |
| Rottenfusser, A | 1 |
| Draxler, W | 1 |
| Omatsu, M | 1 |
| Seki, K | 1 |
| Hasegawa, T | 1 |
| Fukutomi, T | 1 |
| Wengström, Y | 2 |
| Aapro, M | 1 |
| Leto di Priolo, S | 1 |
| Cannon, H | 1 |
| Georgiou, V | 1 |
| Karnon, J | 1 |
| Delea, T | 1 |
| Barghout, V | 1 |
| Hind, D | 1 |
| Ward, S | 1 |
| De Nigris, E | 1 |
| Simpson, E | 1 |
| Carroll, C | 1 |
| Wyld, L | 1 |
| Dizdar, O | 1 |
| Harputluoglu, H | 1 |
| Altundag, K | 1 |
| Tobias, JS | 1 |
| Allred, C | 1 |
| Knox, J | 1 |
| Williams, N | 1 |
| Bishop, H | 1 |
| Larsimont, D | 1 |
| Sasano, H | 1 |
| Carder, P | 1 |
| Cussac, AL | 1 |
| Knox, F | 1 |
| Speirs, V | 1 |
| Pennery, E | 1 |
| Alkasi, O | 1 |
| Meinhold-Heerlein, I | 1 |
| Zaki, R | 1 |
| Fasching, P | 1 |
| Maass, N | 1 |
| Jonat, W | 1 |
| Beckmann, MW | 1 |
| Nabholtz, JM | 1 |
| Gligorov, J | 1 |
| Brunetto, VL | 1 |
| VanLe, L | 1 |
| Bell, J | 1 |
| Walker, JL | 1 |
| Lee, RB | 1 |
| Lavrenkov, K | 1 |
| Man, S | 1 |
| Geffen, DB | 1 |
| Cohen, Y | 1 |
| Ravdin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy[NCT00295620] | Phase 3 | 3,484 participants (Actual) | Interventional | 2004-03-01 | Completed | ||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| Breast Cancer Index (BCI) Registry[NCT04875351] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2021-04-14 | Recruiting | |||
| Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study[NCT03503799] | 1,191 participants (Actual) | Observational [Patient Registry] | 2018-07-17 | Active, not recruiting | |||
| Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.[NCT00291759] | Phase 3 | 3,858 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| International Breast Cancer Intervention Study II (IBIS-II) (DCIS)[NCT00072462] | Phase 3 | 2,980 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.[NCT03002766] | Phase 2 | 224 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer[NCT00265759] | Phase 3 | 622 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study[NCT01953588] | Phase 3 | 1,473 participants (Actual) | Interventional | 2013-12-13 | Active, not recruiting | ||
| Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer[NCT04895761] | Phase 1 | 6 participants (Actual) | Interventional | 2021-09-10 | Active, not recruiting | ||
| Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer.[NCT04496492] | Phase 2 | 50 participants (Actual) | Interventional | 2016-02-09 | Completed | ||
| Impact of Body Mass Index on Outcomes of Breast Cancer Management (Retrospective Study)[NCT03429504] | 300 participants (Anticipated) | Observational | 2018-02-12 | Not yet recruiting | |||
| Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE)[NCT01745289] | 2,671 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer[NCT02955394] | Phase 2 | 61 participants (Actual) | Interventional | 2017-09-21 | Active, not recruiting | ||
| An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)[NCT04770272] | Phase 2 | 416 participants (Actual) | Interventional | 2021-03-01 | Active, not recruiting | ||
| A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen[NCT00003140] | Phase 3 | 5,187 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival. (NCT00295620)
Timeframe: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of overall survival. (NCT00295620)
Timeframe: Overall survival was defined as the time from two years after randomization to death due to any cause, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of lowering the risk of contralateral breast cancer. Subjects without contralateral breast cancer event were censored at the last date when they were known to be contralateral breast cancer free. (NCT00295620)
Timeframe: Risk of contralateral breast cancer was defined as the time from two years after randomization to first occurrence of new contralateral breast cancer, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine the effect of 2 years versus 5 years of additional Anastrozole after 5 years of adjuvant endocrine therapy on the time to first clinical fracture. Patients without clinical fractures where censored at their last therapy visit (approximately 5 years after randomization). (NCT00295620)
Timeframe: Time to first clinical fracture was defined as time to first clinical fracture, in the period from 2 years until 5 years after randomization for each patient.
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of lowering the risk of secondary carcinoma. Subjects without secondary cancer event were censored at the last date when they were known to be secondary cancer free. (NCT00295620)
Timeframe: Risk of secondary carcinoma was defined as the time from two years after randomization to first occurrence of new secondary cancer without new breast cancer (local or contralateral), assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
The primary aim is to assess the anti-tumor effect in terms of pathologic CR rates of neo-adjuvant chemotherapy in patients with T2-T4c, any N, M0 breast cancer (by clinical staging) who are endocrine therapy resistant (that is, their Ki-67 level is >10 after 2-4 week of neo-adjuvant endocrine therapy alone). The pCR rate (percentage) for neo-adjuvant chemotherapy is defined as 100 times the number of eligible patients with no histologic evidence of invasive tumor cells in the surgical breast specimen and the axillary or sentinel lymph nodes divided by the total number of eligible patients who received neo-adjuvant chemotherapy. (NCT00265759)
Timeframe: Up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort B Arm II: Week 2 Ki67 > 10% | 5.7 |
The clinical response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose disease meets the WHO criteria for complete or partial response prior to surgery divided by the total number of eligible patients randomized to that treatment. For each treatment arm, a 95% binomial confidence interval will be constructed for the true clinical response rate. Complete Response (CR): The disappearance of all known disease based on a comparison between the measurements at baseline and the Week 16 visit. Partial Response (PR): A 50% or greater decrease in the product of the bi-dimensional measurements of the lesion (total tumor size) based on a comparison between the measurements at baseline and the Week 16 visit. In addition there can be no appearance of new lesions or progression of any lesion. (NCT00265759)
Timeframe: Up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 62.9 |
| Cohort A Arm II: Letrozole | 74.8 |
| Cohort A Arm III: Anastrozole | 69.1 |
The rate (percentage) of improved surgical outcome for patients considered marginal for breast conservation surgery prior to therapy for Cohort A is reported below for each treatment arm. Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of improved surgical outcome (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 85.2 |
| Cohort A Arm II: Letrozole | 77.4 |
| Cohort A Arm III: Anastrozole | 86.4 |
Rate (percentage) of Improved surgical outcome for patients designated as candidates for mastectomy prior to therapy (Cohort A). Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 48.1 |
| Cohort A Arm II: Letrozole | 42.1 |
| Cohort A Arm III: Anastrozole | 60.0 |
For those patients who undergo a sentinel lymph node dissection or an axillary lymph node dissection (at least 6 nodes examined with Hematoxylin & Eosin Staining), the LNI rate (percentage) is defined as 100 times the proportion of eligible patients randomized to that treatment with at least one positive node. For each neo-adjuvant endocrine treatment, a 95% binomial confidence interval will be constructed for its true LNI rate. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 41.1 |
| Cohort A Arm II: Letrozole | 48.2 |
| Cohort A Arm III: Anastrozole | 44.1 |
The pathologic complete response is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes. The pathologic complete response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose surgical specimen is such that there is no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes divided by the total number of eligible patients randomized to that treatment. For each neo-adjuvant endocrine treatment pair, a 95% binomial confidence interval will be constructed for the true difference in the pCR between these 2 treatments. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 1.7 |
| Cohort A Arm II: Letrozole | 0.0 |
| Cohort A Arm III: Anastrozole | 0.0 |
Incidence of the most common grade 3+ toxicities reported to be probably, possibly, or definitely related to treatment as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (Cohort A) At each treatment evaluation, the type, severity, and attribution of each adverse event reported will be assessed using the NCI-CTCAE definitions. For each treatment, the percentage of patients who developed a severe (grade 3+) toxicity considered possibly, probably or definitively related to treatment will be determined. (NCT00265759)
Timeframe: Up to 30 days after drug therapy
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Fatigue | Hot flashes/flushes | Joint pain | |
| Cohort A Arm I: Exemestane | 2 | 2 | 2 |
| Cohort A Arm II: Letrozole | 2 | 4 | 3 |
| Cohort A Arm III: Anastrozole | 3 | 2 | 2 |
The strength of AR signaling was measured by the percentage of downstream AR-regulated genes that were expressed. (NCT02955394)
Timeframe: 16 Weeks
| Intervention | percentage of genes expressed (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 85 |
| Fulvestrant With Enzalutamide | 80 |
Disease-free survival is defined as the time in months from the start of fulvestrant until documented disease progression or death. Complete and partial response for the single drug arm and combination of enzalutamide/fulvestrant arm separately. (NCT02955394)
Timeframe: 15 months
| Intervention | months (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 3.6 |
| Fulvestrant With Enzalutamide | 3.7 |
"The preoperative endocrine prognostic index (PEPI) is a validated measure of pathologic response to endocrine therapy. It is a model that combines estrogen receptor (ER) level, pathologic tumor site, nodal status, and Ki67 score at the time of surgery to predict subsequent risk of cancer recurrence.~PEPI scoring is typically discretized into three risk groups: 0 (low risk of recurrence and best outcome), 1-3 (intermediate risk), and >= 4 (high risk). This study was concerned only with the distinction between zero and non-zero PEPI scores. Zero is the minimum score, and there is no maximum score. Lower scores are better." (NCT02955394)
Timeframe: 16 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant Without Enzalutamide | 2 |
| Fulvestrant With Enzalutamide | 8 |
25 reviews available for anastrozole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2019 |
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2020 |
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms | 2014 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2015 |
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometria | 2016 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2017 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neopla | 2009 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neopl | 2010 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm | 2011 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Human | 2012 |
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Topics: Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recur | 2012 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2002 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzy | 2003 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; De | 2004 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Human | 2007 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
34 trials available for anastrozole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Progno | 2022 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast N | 2023 |
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adj | 2021 |
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brea | 2021 |
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Topics: Adult; Aged; Anastrozole; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Lo | 2021 |
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epi | 2017 |
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; | 2018 |
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Cystadenoc | 2019 |
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; CA- | 2019 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fol | 2013 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bre | 2014 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Surviva | 2009 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplas | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adj | 2004 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Hum | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Ther | 2007 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcino | 2000 |
65 other studies available for anastrozole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
Topics: Aged; Aminopyridines; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidaz | 2021 |
[A Case of Late Recurrence of Breast Cancer with Chest Wall Recurrence 43 Years after Surgery].
Topics: Adult; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurr | 2021 |
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Pro | 2020 |
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Genetic Pred | 2021 |
Molecular Drivers of Onco
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurr | 2021 |
Switching of Hormone Therapies in Breast Cancer Women.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Dise | 2021 |
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Loc | 2020 |
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genetic Testing; Human | 2021 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2017 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival | 2018 |
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Th | 2017 |
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2018 |
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive.
Topics: Anastrozole; Aromatase; Estrogens; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pa | 2019 |
Long-Term Survival and Complete Response to
Topics: Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Surviva | 2019 |
[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Fem | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tum | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neop | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regu | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor | 2014 |
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Female; Humans; | 2014 |
Remission of metastatic primary mucinous carcinoma of the skin with anastrozole.
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Female; Head and Nec | 2014 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplas | 2015 |
Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Endometrial Neoplasms; Female; Humans; | 2015 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; H | 2016 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamil | 2017 |
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Immunohist | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neopl | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neo | 2008 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Mid | 2009 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection | 2010 |
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; En | 2011 |
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combi | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bioma | 2011 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neopl | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2012 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; An | 2003 |
Doctors test drug to prevent cancer in high risk women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2003 |
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combin | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chol | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Alternative to tamoxifen effective for preventing breast cancer recurrence.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2005 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Ant | 2006 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2005 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2006 |
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Hu | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Mod | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost | 2006 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit | 2008 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; H | 2007 |
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Surviva | 2009 |
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhi | 2002 |